Bcl-2-mediated_JJ
drug_NN
resistance_NN
:_:
inhibition_NN
of_IN
apoptosis_NN
by_IN
blocking_VBG
nuclear_JJ
factor_NN
of_IN
activated_VBN
T_NN
lymphocytes_NNS
-LRB-_-LRB-
NFAT_NN
-RRB-_-RRB-
-_:
induced_VBN
Fas_NN
ligand_NN
transcription_NN
._.

Bcl-2_NN
inhibits_VBZ
apoptosis_NN
induced_VBN
by_IN
a_DT
variety_NN
of_IN
stimuli_NNS
,_,
including_VBG
chemotherapy_NN
drugs_NNS
and_CC
glucocorticoids_NNS
._.

It_PRP
is_VBZ
generally_RB
accepted_VBN
that_IN
Bcl-2_NN
exerts_VBZ
its_PRP$
antiapoptotic_JJ
effects_NNS
mainly_RB
by_IN
dimerizing_VBG
with_IN
proapoptotic_JJ
members_NNS
of_IN
the_DT
Bcl-2_NN
family_NN
such_JJ
as_IN
Bax_NN
and_CC
Bad_NN
._.

However_RB
,_,
the_DT
mechanism_NN
of_IN
the_DT
antiapoptotic_JJ
effects_NNS
is_VBZ
unclear_JJ
._.

Paclitaxel_NN
and_CC
other_JJ
drugs_NNS
that_WDT
disturb_VBP
microtubule_JJ
dynamics_NNS
kill_VBP
cells_NNS
in_IN
a_DT
Fas_NN
\/_CC
Fas_NN
ligand_NN
-LRB-_-LRB-
FasL_NN
-RRB-_-RRB-
-_:
dependent_JJ
manner_NN
;_:
antibody_NN
to_TO
FasL_NN
inhibits_VBZ
paclitaxel-induced_JJ
apoptosis_NN
._.

We_PRP
have_VBP
found_VBN
that_IN
Bcl-2_NN
overexpression_NN
leads_VBZ
to_TO
the_DT
prevention_NN
of_IN
chemotherapy_NN
-LRB-_-LRB-
paclitaxel_NN
-RRB-_-RRB-
-_:
induced_VBN
expression_NN
of_IN
FasL_NN
and_CC
blocks_VBZ
paclitaxel-induced_JJ
apoptosis_NN
._.

The_DT
mechanism_NN
of_IN
this_DT
effect_NN
is_VBZ
that_IN
Bcl-2_NN
prevents_VBZ
the_DT
nuclear_JJ
translocation_NN
of_IN
NFAT_NN
-LRB-_-LRB-
nuclear_JJ
factor_NN
of_IN
activated_VBN
T_NN
lymphocytes_NNS
,_,
a_DT
transcription_NN
factor_NN
activated_VBN
by_IN
microtubule_JJ
damage_NN
-RRB-_-RRB-
by_IN
binding_VBG
and_CC
sequestering_VBG
calcineurin_NN
,_,
a_DT
calcium-dependent_JJ
phosphatase_NN
that_WDT
must_MD
dephosphorylate_VB
NFAT_NN
to_TO
move_VB
to_TO
the_DT
nucleus_NN
._.

Without_IN
NFAT_NN
nuclear_JJ
translocation_NN
,_,
the_DT
FasL_NN
gene_NN
is_VBZ
not_RB
transcribed_VBN
._.

Thus_RB
,_,
it_PRP
appears_VBZ
that_IN
paclitaxel_NN
and_CC
other_JJ
drugs_NNS
that_WDT
disturb_VBP
microtubule_JJ
function_NN
kill_VBP
cells_NNS
at_IN
least_JJS
in_IN
part_NN
through_IN
the_DT
induction_NN
of_IN
FasL_NN
._.

Furthermore_RB
,_,
Bcl-2_NN
antagonizes_VBZ
drug-induced_JJ
apoptosis_NN
by_IN
inhibiting_VBG
calcineurin_NN
activation_NN
,_,
blocking_VBG
NFAT_NN
nuclear_JJ
translocation_NN
,_,
and_CC
preventing_VBG
FasL_NN
expression_NN
._.

The_DT
effects_NNS
of_IN
Bcl-2_NN
can_MD
be_VB
overcome_VBN
,_,
at_IN
least_JJS
partially_RB
,_,
through_IN
phosphorylation_NN
of_IN
Bcl-2_NN
._.

Phosphorylated_VBN
Bcl-2_NN
can_MD
not_RB
bind_VB
calcineurin_NN
,_,
and_CC
NFAT_NN
activation_NN
,_,
FasL_NN
expression_NN
,_,
and_CC
apoptosis_NN
can_MD
occur_VB
after_IN
Bcl-2_NN
phosphorylation_NN
._.

